Intas Pharmaceutical has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard ...

Coherus BioSciences will see its workforce shrink once again as the result of the recently agreed sale of its Neulasta ...

The pharma industry registered a 7.5% value growth year-on-year for the month of February, with sales of ₹18,781 crore, ...

Among them, the cardiac, gastrointestinal, and antidiabetic therapies saw high value growth of 9.5 per cent, 9.6 per cent, ...

The National Pharmaceutical Pricing Authority (NPPA) has notified the retail price of 53 new drugs based on applications submitted by individual companies, after finalising the same in the latest ...

Telangana: Natco Pharma has appointed Bhimrao Dattu Jadhav as Senior Vice President - Operations (Formulations) for Pharma ...

This remarkable performance by Indian enterprises, both listed and unlisted is highlighted by Axis Bank's Burgundy Private and Hurun India.

Johnson & Johnson (NYSE:JNJ) is suing Samsung Bioepis for breach of contract related to the launch of a biosimilar of J&J's blockbuster drug Stelara, also known as ustekinumab. According to a suit ...

Over the years, the broader pharmaceutical space has witnessed considerable interest from both strategic and institutional investors. For instance, Gujarat-based drugmaker Intas Pharmaceuticals Ltd, ...

the shares of a company engaged in the business of contract manufacturing of formulation for pharmaceutical companies surged nearly 4.3 percent on NSE, after announcing that it will manufacture and ...

One Indian pharmaceutical company dey manufacture unlicensed, highly addictive opioids and dey export dem illegally to West Africa wia dem dey drive a major public health crisis for countries ...